STRIVERDI RESPIMAT Drug Patent Profile
✉ Email this page to a colleague
When do Striverdi Respimat patents expire, and when can generic versions of Striverdi Respimat launch?
Striverdi Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and ninety-four patent family members in forty countries.
The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Striverdi Respimat
Striverdi Respimat was eligible for patent challenges on July 31, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 19, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for STRIVERDI RESPIMAT
| International Patents: | 194 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 2 |
| Patent Applications: | 48 |
| Drug Prices: | Drug price information for STRIVERDI RESPIMAT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for STRIVERDI RESPIMAT |
| What excipients (inactive ingredients) are in STRIVERDI RESPIMAT? | STRIVERDI RESPIMAT excipients list |
| DailyMed Link: | STRIVERDI RESPIMAT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for STRIVERDI RESPIMAT
Generic Entry Date for STRIVERDI RESPIMAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SPRAY, METERED;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for STRIVERDI RESPIMAT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Università degli Studi di Ferrara | Phase 4 |
| Boehringer Ingelheim |
Pharmacology for STRIVERDI RESPIMAT
| Drug Class | beta2-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for STRIVERDI RESPIMAT
US Patents and Regulatory Information for STRIVERDI RESPIMAT
STRIVERDI RESPIMAT is protected by nine US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of STRIVERDI RESPIMAT is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting STRIVERDI RESPIMAT
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Piston-pumping system having o-ring seal properties
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Medicaments for the treatment of chronic obstructive pulmonary disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Device for clamping a fluidic component
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Microstructured high pressure nozzle with built-in filter function
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Device for clamping a fluidic component
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Expired US Patents for STRIVERDI RESPIMAT
International Patents for STRIVERDI RESPIMAT
See the table below for patents covering STRIVERDI RESPIMAT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 325961 | ⤷ Try a Trial | |
| Hungary | 226043 | LOCKING MECHANISM FOR A SPRING-ACTUATED DEVICE AND A FLUID COMPRISING AND ATOMISING DEVICE FOR THIS | ⤷ Try a Trial |
| Colombia | 5720979 | DISPOSITIVO BLOQUEADOR PARA UN MECANISMO TENSOR DE BLOQUEO CON UNA TOMA DE FUERZA ACCIONADA POR RESORTE | ⤷ Try a Trial |
| Lithuania | C1562603 | ⤷ Try a Trial | |
| Estonia | 04634 | Meetod avaga konteineri valmistamiseks ja konteiner, mis on valmistatud sellel meetodil | ⤷ Try a Trial |
| Portugal | 1539368 | ⤷ Try a Trial | |
| Japan | 2003056458 | DEVICE OF MINIATURIZED STRUCTURE FOR PRESSURIZING FLUID | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for STRIVERDI RESPIMAT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1562603 | C300650 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: OLODATEROL, OPTISCHE ISOPMEREN; NAT. REGISTRATION NO/DATE: RVG 112058 20131023; FIRST REGISTRATION: |
| 1562603 | 21/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: OLODATEROL, DESSEN SAEUREHAELTIGEN SALZE MIT PHARMAKOLOGISCH VERTRAEGLICHEN SAEUREN, IM BESONDEREN OLODATEROL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 135232 20131125; FIRST REGISTRATION: MT MA211/00401 20130918 |
| 1562603 | PA2014012,C1562603 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: OLODATEROLIS, JO OPTINIAI IZOMERAI, JO ATSKIRU ENANTIOMERU ARBA RACEMATU MISINIAI, JO RUGSTIES ADITYVINES DRUSKOS SU FRAMAKOLOGINIU POZIURIU PRIIMTINOMIS RUGSTIMIS, O TAIP PAT JO SOLVATAI IR/ARBA HIDRATAI, KONKRECIAI OLODATEROLIS IR OLODATEROLIO CHLORIDAS; NAT. REGISTRATION NO/DATE: LT/1/13/3429/001, LT/1/13/3429/002, LT/1/13/3429/003, LT/1/13/3429/004 20131031; FIRST REGISTRATION: MA211/00401 20130918 |
| 1562603 | 122014000018 | Germany | ⤷ Try a Trial | PRODUCT NAME: OLODATEROL, OPTISCHE ISOMERE DAVON, MISCHUNGEN VON ISOMEREN DAVON, SAEUREADDITIONSSALZE DAVON MIT PHARMAKOLOGISCH UNBEDENKLICHEN SAEUREN, SOWIE SOLVATE UND/ODER HYDRATE DAVON, INSBESONDERE OLODATEROL UND OLODATEROLHYDROCHLORID; NAT. REGISTRATION NO/DATE: 87146.00.00 20131126; FIRST REGISTRATION: MALTA MA 211/00401 20130918 |
| 1562603 | SPC/GB14/023 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: OLODATEROL OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: MT MA 211/00401 20130918; UK PL 14598/0093 20131010 |
| 1562603 | 159 5009-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: OLODATEROL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 14/0394/13-S 20131029; FIRST REGISTRATION: MT MA211/00401 20130918 |
| 1562603 | C20140010 00101 | Estonia | ⤷ Try a Trial | PRODUCT NAME: OLODATEROOL;REG NO/DATE: EE 825513 03.10.2013 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
